Clinical Trial: A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy

U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07803783) titled 'A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy' on Aug. 31.

Brief Summary: The purpose of this study is to evaluate the safety and efficacy of an investigational B7-H3 antibody drug-conjugate administered as monotherapy, compared with standard of care (SOC) chemotherapy in metastatic pancreatic cancer patients who have failed prior Gemcitabine-based systemic therapy.

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Metastatic Pancreatic Cancer Pancreatic Ductal Adenocarcinoma (P...